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Interventional Cardiology
Platelet Aggregation Abnormalities in Patients with Stent Thrombosis
One percent of patients undergoing stent placement develop stent thrombosis(ST). Although technical aspects of stent placement are known to increase the
risk, intrinsic abnormalities in patients, such as resistance to aspirin or clopidogrel,may
also predict ST. Two papers in this issue compare platelet reactivity in subjects with
prior ST to controls with coronary artery disease and normals. The paper by
Wenaweser and colleagues finds that patients with prior ST have higher rates of aspirin
resistance, and as a result have higher rates of combined aspirin and clopidogrel
resistance to adenosine diphosphate-induced platelet aggregation. In a similar study,
Ajzenberg and colleagues found that platelet aggregation and rates of aspirin or
clopidogrel resistance are similar in subjects with and without a history of ST, but that
those with previous ST have higher rates of shear-induced platelet aggregation despite
being treatedwith aspirin and clopidogrel. These studies indicate a role for resistance to
antiplatelet drugs in stent thrombosis. See pages 1748 and 1753.
Coronary Artery Disease
Adenosine in the Treatment of AMI (AMISTAD-II)
Animal models have suggested that adenosine may improve post-infarction out-comes by limiting reperfusion injury or improving infarct-related artery patency.
Although the Acute Myocardial Infarction Study of Adenosine (AMISTAD-I) sug-
gested that adenosine infusion at the time of reperfusion limited infarct size, it was
underpowered to detect improvement in clinical outcomes. The AMISTAD-II trial
randomized subjects presenting with acute anterior ST-segment elevation myocardial
infarction either to placebo or a 3-h infusion of adenosine and reperfusion with either
thrombolytics or percutaneous coronary intervention. While the improvement in
clinical outcomes was not statistically significant, a substudy showed a dose related
reduction in thallium measured infarct size with adenosine. The infusions were
generally well tolerated. Adenosine may be a useful adjunct to reperfusion strategies,
although the best dose and the magnitude of benefit remain undefined. See page
1775.
Heart Failure
Elevated ESR Predicts Risk of Heart Failure 10 Years Later
Multiple makers of inflammation have been associated with an adverse prognosisinpatientswith congestiveheart failure (CHF). In a large, long-termstudy from
Sweden, erythrocyte sedimentation rate (ESR)wasmeasured in over 2,000men age 50
years who were followed for up to 30 years for infarctions or hospitalization for CHF.
ESR was found to be a significant predictor of subsequent CHF, a relationship that
remained after adjusting for interim myocardial infarction and several known cardio-
vascular risk factors. For ESR above or below the median of 6 mm/h, the incidence of
CHF does not appear to diverge for the first 10 years, suggesting that ESR elevation is
a very early marker of increased risk for CHF. See page 1802.
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Cardiac Imaging
A Trio of MRI Abnormalities Can Diagnose Myocarditis
Acute myocarditis is a heterogeneous disorder that can be difficult to diagnoseclinically. Cardiac magnetic resonance imaging (MRI) can detect several types of
injury thatmay be present in acutemyocarditis. Early gadolinium enhancement (gRE)
can detect hyperemia and/or capillary permeability. Late gREdetects areas of cell death
that are unable to extrude the contrast. Areas with relatively high T2 signal intensity
have increased water content and may represent areas of edema. Abdel-Aty and
colleagues studied 25 patients with suspected acute myocarditis using a standardized
protocol that compared all three of these parameters. Each of the parameters had fair
sensitivity or specificity alone, but requiring two out of three abnormalities resulted in
a diagnostic accuracy of nearly 80% with high specificity and acceptable sensitivity.
See page 1815.
Heart Rhythm Disorders
Prevention of Atrial Fibrillation with ACE Inhibitors or ARBs
Healey and colleagues conducted a meta-analysis of 11 studies which reported onthe efficacy of either angiotensin-converting enzyme (ACE) inhibitors or angio-
tensin receptor blockers (ARBs) to prevent atrial fibrillation. Overall there was a 28%
reduction, although there was a wide range of efficacy depending on the study
population. The greatest efficacy was seen in subjects with significant left ventricular
dysfunction or immediately post cardioversion. Lesser effects were seen in subjects post
myocardial infarction or in those with hypertension without left ventricular hypertro-
phy. As most of these studies used a placebo rather than an active treatment compari-
son, more studies are needed to determine if this effect is specific to inhibitors of the
renin-angiotension-aldosterone-system or is the result of more aggressive blood pres-
sure lowering. See page 1832.
Preclinical Studies
Proof of Concept for a Percutaneous LVAD
This paper describes the development of a percutanouesly deliverable left ventric-ular assist device (LVAD) and its use in an animal model of cardiogenic shock.
Thedevice is inserted through a9-F sheath in the femoral artery, retrograde into the left
ventricle. A sleeve is then opened exposing the pumpmechanismwhich then expands.
The pump is capable of generating up to 4 l/min of blood flow with a 60 mmHg rise
in pressure.When the pump is ready to bewithdrawn, the guiding catheter is advanced
and the pump returns into the sheath and is removed percutaneously. In sheep, the
device is easily inserted with minimal damage to either the aortic valve or the left
ventricle and with an acceptable amount of hemolysis. The pump is capable of
improving cardiac output and blood pressure by approximately 50% after the induc-
tion of cardiogenic shock. See page 1856.
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